Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Porto SA, Birdsall GA, Harper NW, Honeywell ME, Leighow SM, Naylor TE, Ward KM, Wesley MK, Pritchard JR, Lee MJ. Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition. J Biol Chem. 2026 May; 302(5):111414.
-
Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P, Jiang Y, Xu MJ, Lei KJ, Qu S, Wang XH, Jin YS, Zhao B, Dai R, Wang FH, Xu RH. Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med. 2026 04 10; 7(4):101029.
-
Shin JH, Kim JY, Kim SH, Kang Y, Lee HJ, Kim MJ, Choi J, Jeong SK, Park SO, Cho YB, Kim KK, Shim JH, Chun E, Lee KY. USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis. Cell Death Dis. 2025 Dec 19; 16(1):894.
-
Shin JH, Kim JY, Kim MJ, Kang Y, Lee HJ, Choi B, Lee JS, Kwon D, Kim SH, Sung Y, Kim DH, Shim JH, Chun E, Lee KY. PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways. Exp Mol Med. 2025 Nov; 57(11):2559-2573.
-
Fuster-Matanzo A, Pic?-Peris A, Bellv?s-Bataller F, Jimenez-Pastor A, Weiss GJ, Mart?-Bonmat? L, L?zaro S?nchez A, Bazaga D, Banna GL, Addeo A, Camps C, Seijo LM, Alberich-Bayarri ?. Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods. Eur Radiol. 2026 Mar; 36(3):2157-2185.
-
Raquel-Cunha A, Pinheiro J, Marques RF, Font?o P, Cardoso-Carneiro D, Mendes A, Gomes INF, Laus AC, da Silva-Oliveira RJ, Reis RM, Martinho O. RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies. Mol Oncol. 2025 Nov; 19(11):3205-3222.
-
Yerramilli VS, Lin G, Reisinger JL, Hemmerlin RM, Lindberg SK, Plante K, Ross AH, Gericke A, Scarlata S. The scaffolding protein IQGAP1 enhances EGFR signaling by promoting oligomerization and preventing degradation. J Biol Chem. 2024 11; 300(11):107844.
-
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.
-
Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, J?nne PA, Mino-Kenudson M, Swanson S, Wright CD, Kozono D, Marcoux P, Piotrowska Z, Sequist LV, Willers H. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024 07 05; 29(7):609-618.
-
Bhalerao N, Chakraborty A, Marciel MP, Hwang J, Britain CM, Silva AD, Eltoum IE, Jones RB, Alexander KL, Smythies LE, Smith PD, Crossman DK, Crowley MR, Shin B, Harrington LE, Yan Z, Bethea MM, Hunter CS, Klug CA, Buchsbaum DJ, Bellis SL. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression. JCI Insight. 2023 10 09; 8(19).